Tislelizumab as Cross-line Treatment for Advanced NSCLC

Advanced Non-small-cell Lung Cancer Clinical Trial

Official title: Tislelizumab Combined With Docetaxel for Cross-line Treatment of First-line Resistant Advanced NSCLC，a Phase II Clinical Study

Status Enrolling by invitation

Clinical Trial Summary

This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and continuing Tislelizumab in combination with docetaxel. The primary study endpoint of this study is measured by progression-free survival (PFS).

1. Tislelizumab: The recommended dose is 200 mg/dose administered every three weeks on the first day of each cycle.

2. Docetaxel: 60-75 mg/m2 every 3 weeks, administered on day 1 of each cycle.

3. Treatment cycle: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced Non-small-cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung

• NCT number: NCT05192681
• Study type: Interventional
• Source: Fujian Cancer Hospital
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: October 10, 2021
• Completion date: October 10, 2023